Search
Proflavine
go.drugbank.com/drugs/DB01123ApprovedInvestigational3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings.
Mixtures: Kerr 100 Triple Dye Dispos-ATolbutamide
go.drugbank.com/drugs/DB01124ApprovedTolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of...
International brands: OrinaseProducts: Orinase 1gm, Orinase 0.5gmSulfinpyrazone
go.drugbank.com/drugs/DB01138ApprovedA uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Amifostine
go.drugbank.com/drugs/DB01143ApprovedInvestigationalA phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Categories: Compounds used in a research, industrial, or household settingSulfoxone
go.drugbank.com/drugs/DB01145ApprovedSulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.
Cloxacillin
go.drugbank.com/drugs/DB01147ApprovedInvestigationalVet approvedA semi-synthetic penicillin antibiotic which is a chlorinated derivative of [oxacillin].
Nefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnDrug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.
Alisertib
go.drugbank.com/drugs/DB05220InvestigationalAlisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...
Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index